Press Releases March 31, 2026

NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity

NEXGEL delays 2025 financial results call to detail potential transaction with Celularity Inc.

By Hana Yamamoto NXGL
NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity
NXGL

NEXGEL, Inc. has rescheduled its Q4 and full-year 2025 financial results conference call to April 8, 2026, to provide shareholders with more detailed information about its proposed transaction with Celularity Inc. The company concurrently filed its 2025 Annual Report with the SEC. NEXGEL specializes in healthcare, beauty, and OTC hydrogel products and maintains strategic contract manufacturing partnerships with consumer healthcare companies.

Key Points

  • NEXGEL postponed its 2025 financial results call to discuss the potential deal with Celularity, signaling strategic corporate developments.
  • The company filed its Annual Report on Form 10-K for 2025, providing comprehensive financial disclosures to shareholders and the SEC.
  • NEXGEL operates in healthcare and consumer products sectors, with a focus on hydrogel technologies and contract manufacturing agreements impacting healthcare and consumer goods markets.

LANGHORNE, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its fourth quarter and fiscal year 2025 financial results conference call to April 8, 2026 at 4:30 P.M. ET to provide additional time for the Company to provide shareholders with greater detail regarding its previously announced proposed transaction with Celularity Inc.

The Company will file its Annual Report on Form 10-K for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission today, March 31, 2026.

Fourth Quarter and Full Year 2025 Financial Results Conference Call Details:
Date: April 8, 2026
Time: 4:30 P.M. ET
Live Call: 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International)
Webcast: Events and Presentations

About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.

Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our ability to consummate the potential acquisition and the related additional investment. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.

Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@KCSA.com


Risks

  • Uncertainty surrounding the completion and terms of the proposed transaction with Celularity, which could materially affect the company's future performance.
  • Forward-looking statements in the release highlight risks related to business prospects, including potential difficulties in consummating acquisitions or investments.
  • Economic and regulatory factors impacting contract manufacturing and healthcare product markets could affect NEXGEL's operational results and financial conditions.

More from Press Releases

Jena Acquisition Corporation II Announces Non-Compliance with Section 802.01B of the NYSE Listed Company Manual which Requires the Company to Maintain a Minimum of 300 Public Stockholders Apr 3, 2026 Midland States Bancorp, Inc. To Announce First Quarter 2026 Financial Results On Thursday, April 23 Apr 3, 2026 Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 3, 2026 Multi-Sensor Data Labeling and AI Data Operations: What Enterprise AV Teams Apr 3, 2026 Wix Announces Final Results of Modified Dutch Auction Tender Offer Apr 3, 2026